Collegium Pharmaceutical, Inc. (COLL)

36.42 +0.58 (+1.62%) 收市：04:00PM EDT

Collegium Pharmaceutical, Inc.

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
United States
781 713 3699
https://www.collegiumpharma.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 197

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.	Co-Founder & Independent Chairman	110k	無	1964
Mr. Joseph J. Ciaffoni	President, CEO & Director	1.45M	770.46k	1971
Ms. Colleen Tupper	Executive VP & CFO	782.64k	無	1976
Ms. Shirley R. Kuhlmann	Executive VP, General Counsel, Chief Administrative Officer & Secretary	788.45k	252.97k	1984
Mr. Scott Dreyer	Executive VP & Chief Commercial Officer	693.54k	無	1972
Dr. Thomas B. Smith FAAFP, M.D.	Executive VP & Chief Medical Officer	693.27k	無	1961
Dr. Christopher Shayne James M.D.	Vice President of Investor Relations	無	無	無
Mr. Bart J. Dunn	Executive Vice President of Strategy & Corporate Development	無	無	無
Mr. Scott Sudduth	Head of Technical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

公司管治

截至 2024年4月1日 止，Collegium Pharmaceutical, Inc. 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：9；董事會：4；股東權利：2；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。